SCHEMBL16610053

SCHEMBL16610053

COc1ccccc1C(=O)Oc1ccc(CO[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.60
NPSR1 Q6W5P4 2/20 0.60
HPGD P15428 1/20 0.53
XBP1 P17861 1/20 0.53
KMT2A Q03164 5/20 0.49
ESR1 P03372 2/20 0.49
MEN1 O00255 2/20 0.49
PTGS2 P35354 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
ALDH1A1 P00352 2/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ESR2 Q92731 1/20 0.44
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
ATM Q13315 1/20 0.42
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22502975 0.94 MAPT (0.54) MAPTNPSR1HPGDXBP1KMT2A
SCHEMBL16610055 0.89 PTGS2 (0.61) MAPTNPSR1HPGDXBP1KMT2A
SCHEMBL22502970 0.85 PTGS2 (0.56) MAPTNPSR1HPGDXBP1KMT2A
SCHEMBL16610051 0.82 KMT2A (0.46) MAPTNPSR1HPGDKMT2AMEN1
SCHEMBL16610043 0.81 MAPT (0.55) MAPTKMT2AMEN1ALDH1A1TSHR
SCHEMBL16610054 0.80 SMN1; SMN2 (0.51) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL16610070 0.80 PTGS2 (0.44) MAPTNPSR1KMT2APTGS2CYP1A2
SCHEMBL16599389 0.79 TSHR (0.50) MAPTHPGDKMT2AMEN1CYP1A2
SCHEMBL16599350 0.78 MAPT (0.65) MAPTNPSR1HPGDXBP1KMT2A
SCHEMBL18020584 0.78 PRSS1 (0.46) MAPTHPGDKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 EP disclosed
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases UNIVERSITÄT ZU KOLN (DE) 2020-10-06 US disclosed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 EP disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
WO-2015044177-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES APC, BRCA1, VHL MAPT 1257/4885NPSR1 2377/4885HPGD 41/4885
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases APC, BRCA1, VHL MAPT 1257/4885NPSR1 2377/4885HPGD 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.